FY2024 Earnings Forecast for ZNTL Issued By Leerink Partnrs

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a report issued on Wednesday, January 29th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($2.35) per share for the year, up from their previous estimate of ($2.68). The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals' Q4 2024 earnings at ($0.68) EPS, FY2025 earnings at ($2.01) EPS, FY2026 earnings at ($1.82) EPS and FY2027 earnings at ($1.76) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company dropped their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. UBS Group dropped their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Guggenheim reduced their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. HC Wainwright decreased their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, January 29th. Finally, Wedbush reissued a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $8.24.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock traded up $0.02 during trading on Monday, reaching $2.16. 3,278,452 shares of the company were exchanged, compared to its average volume of 2,950,098. Zentalis Pharmaceuticals has a 52-week low of $1.61 and a 52-week high of $18.07. The company has a market capitalization of $153.92 million, a P/E ratio of -0.87 and a beta of 1.82. The stock's 50 day simple moving average is $2.81 and its two-hundred day simple moving average is $3.21.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka acquired 60,000 shares of the stock in a transaction dated Friday, January 31st. The stock was acquired at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.60% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $68,000. Charles Schwab Investment Management Inc. raised its stake in Zentalis Pharmaceuticals by 22.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company's stock worth $1,507,000 after acquiring an additional 91,152 shares in the last quarter. Anfield Capital Management LLC lifted its position in Zentalis Pharmaceuticals by 100.0% in the fourth quarter. Anfield Capital Management LLC now owns 129,318 shares of the company's stock valued at $392,000 after acquiring an additional 64,659 shares during the last quarter. Ieq Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at approximately $46,000. Finally, Savant Capital LLC acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $72,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.